discover and develop new drugs, diagnostics, and research products
improve their drug pipelines
identify and evaluate potential partners
develop new applications for their technologies
penetrate new markets|
|
|---|
Haberman Associates is a Boston-based consulting firm, founded in 1993, that specializes in science and technology strategy for life science companies.Consulting for effective life science R&D and partnering
We assist your company to achieve its business goals in new product development and commercialization. Our focus is on effective R&D, business development, and partnering.
Clients have used our consulting services to help them:
For additional information about how we can assist your company, please
see
"About Haberman
Associates". Or use our site
map to navigate our entire site.
For an initial discussion of your company's needs, or if you have any
questions about our firm, please contact
us.
Haberman Associates is a member of the Biopharmaceutical Consortium, an expert team of consultancies formed in 1997 to assist life science companies, research groups, and emerging enterprises.
__________________________________________________
May 9, 2008: Blood-Brain Barrier: Bridging Options for Drug Discovery
and Development published by Cambridge Healthtech Institute. See
our News Page.
January
1, 2008:
"Addressing Unmet Type 2
Diabetes Needs" published in Genetic Engineering News. See our
News Page or
the PDF.
September
6, 2007: Dr. Haberman quoted on Pharmawire
on new drugs for diabetes and obesity. See our News
Page.
Our online
articles:
"Addressing
Unmet Type 2 Diabetes Needs"
(Published in the January 1, 2008
issue of Genetic Engineering News.)
"Recent
Clinical Developments in Type 2 Diabetes: Preventing Diabetes and Preventing
Cardiovascular Events in Diabetics"
(Published in the October
19, 2006 issue of CHI's Pharma DD.)
"Safety
Issues Hamper Dual PPAR Agonists: Is Partial Antagonism the Solution?"
(Published in the September
22, 2006 issue of CHI's Pharma DD.)
"Breaking
the Obesity Barrier: Near-Term Prospects for Breakthrough Treatments"
(Published in the December
22, 2005 issue of CHI's PharmaWeek.)
"Strategies
to Move Beyond Target Validation: Targets and Druggability for Small
and
Large Molecule Drugs"
(Published in the December 1, 2005
issue of Genetic Engineering News.)
"Therapeutic
Strategies in Animal Models: the Case of Alzheimer's Disease."
(Published in the September 15,
2004 issue of Genetic Engineering News.)
About Haberman Associates |
About Allan B. Haberman |
Our publications|
Speaking |
News Page |
Contact us ||Site
map